Overview

Evaluate the Safety, Tolerability, and PK of EP547 in Healthy Subjects and Subjects With Cholestatic or Uremic Pruritus

Status:
Active, not recruiting

Trial end date:
2021-06-30

Target enrollment:

Participant gender:

Summary

This first in human, Phase 1/1b trial will evaluate the safety, tolerability, and pharmacokinetics of single and multiple ascending doses of EP547 in healthy subjects and subjects with cholestatic or uremic pruritus.

Phase:

Phase 1

Details

Lead Sponsor:

Escient Pharmaceuticals, Inc

Collaborator:

Novotech (Australia) Pty Limited